Patents by Inventor Andrea Bolognesi

Andrea Bolognesi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Type-1 ribosome-inactivating protein
    Patent number: 7479552
    Abstract: The invention relates to a novel ribosome-binding protein derived from Bougainvillea spectabilis having a molecular weight of about 26,000 daltons by polyacrylamide gel electrophoresis under reducing and non-reducing conditions, a pI of about 9.0, and a specified amino-terminal amino acid sequence. The invention further relates to a conjugate of the protein with a targeting ligand, such as an antibody, to form an immunotoxin. The protein and the conjugate are useful in therapy, for example, in the control of tumour cells or viruses.
    Type: Grant
    Filed: January 16, 2004
    Date of Patent: January 20, 2009
    Assignee: Tanox Pharma B.V.
    Inventors: Fiorenzo Stirpe, Andrea Bolognesi
  • Type-1 ribosome-inactivating protein
    Publication number: 20040266994
    Abstract: The invention relates to a novel ribosome-binding protein derived from Bougainvillea spectabilis having a molecular weight of about 26,000 daltons by polyacrylamide gel electrophoresis under reducing and non-reducing conditions, a pI of about 9.0, and further comprising a specified amino-terminal amino acid sequence, as well as to a conjugate of said protein with a targeting ligand, such as an antibody, to form an immunotoxin. The protein and the conjugate are useful in therapy, for example in the control of tumour cells or viruses.
    Type: Application
    Filed: January 16, 2004
    Publication date: December 30, 2004
    Inventors: Fiorenzo Stirpe, Andrea Bolognesi
  • Type-1 ribosome-inactivating protein
    Patent number: 6680296
    Abstract: The invention relates to a novel ribosome-binding protein derived from Bougainvillea speotabilis having a molecular weight of about 26,000 daltons by polyacrylamide gel electrophoresis under reducing and non-reducing conditions, a ph of about 9.0, and further comprising a specified amino-terminal amino acid sequence, as well as to a conjugate of said protein with a targeting ligand, such as an antibody, to form an immunotoxin. The protein and the conjugate are useful in therapy, for example in the control of tumour calls or viruses.
    Type: Grant
    Filed: March 10, 2000
    Date of Patent: January 20, 2004
    Assignee: Tanox Pharma B.V.
    Inventors: Fiorenzo Stirpe, Andrea Bolognesi